Opus Genetics (IRD) EBIT (2022 - 2024)
Opus Genetics (IRD) has disclosed EBIT for 6 consecutive years, with -$13.3 million as the latest value for Q4 2021.
- On a quarterly basis, EBIT changed N/A to -$13.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was -$22.7 million, a N/A change, with the full-year FY2022 number at $18.2 million, up 180.27% from a year prior.
- EBIT was -$13.3 million for Q4 2021 at Opus Genetics, down from -$3.1 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$13.3 million in Q4 2021 to a low of -$13.3 million in Q4 2021.